WO2000052029A1 - Derive de sterol hydrosoluble inhibant l'absorption de cholesterol et procede d'elaboration - Google Patents
Derive de sterol hydrosoluble inhibant l'absorption de cholesterol et procede d'elaboration Download PDFInfo
- Publication number
- WO2000052029A1 WO2000052029A1 PCT/KR2000/000170 KR0000170W WO0052029A1 WO 2000052029 A1 WO2000052029 A1 WO 2000052029A1 KR 0000170 W KR0000170 W KR 0000170W WO 0052029 A1 WO0052029 A1 WO 0052029A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phytosterol
- compound
- polyethylene glycol
- group
- water
- Prior art date
Links
- 0 C*(*)O**(C)C*O[N+]([O-])[S@](C)=* Chemical compound C*(*)O**(C)C*O[N+]([O-])[S@](C)=* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
Definitions
- the present invention relates to water-soluble sterol derivatives for inhibiting cholesterol absorption and process for preparing the same.
- phytosterols which originate from plants, are believed to lower serum cholesterol levels, particularly LDL-cholesterol levels, by inhibiting absorption of cholesterol in the intestine through competition with cholesterol. It is believed that phytosterols do not significantly affect the biosynthesis of cholesterol or have significant side effects.
- Phytosterols are steroid alcohols found in higher plant and include stigmasterol, spinasterol, campesterol and sitosterol, which has , ⁇ and ⁇ -types.
- ⁇ - sitosterol 24-ethyl-5 ⁇ -cholestene-3 ⁇ -ol
- ⁇ -sitosterol ester compounds generated from a substitution of fatty acid have also been reported as having a cholesterol lowering effect similar to that of ⁇ - sitosterol (see: Mattson, F. H. et al . , J. Nutr . , 107:1139- 1146, 1977) .
- ⁇ -sitosteryl oleate when 2 grams of ⁇ -sitosteryl oleate were dosed to adult humans for 5 days, cholesterol absorption was reduced by about 33% (see : Mattson, F. H. et al., Am . J. Clin . Nutr . , 35:697-700, 1982).
- ⁇ -sitosterol is known to be the major component of Zea mays L . which is used for treating gingivitis and alveolitis.
- phytosterols Despite their cholesterol-lowering effect, phytosterols have not been in wide use, since phytosterols are not soluble in water or in oil, their use as food additives for reducing serum cholesterol limiting levels. That is, due to their hydrophobic and lipophobic properties, phytosterols have been formulated primarily in tablet or capsule form.
- polyoxyethylene phytostanol ether compounds have been used as an emulsifier for cosmetics ( ⁇ j ⁇ e: U.S. Patent Nos . 5,846,458, 5,593,622 and 5,676,971).
- phytosterols are coupled to polyethylene glycols (PEGs) by relatively permanent ether bonds.
- PEGs polyethylene glycols
- phytosterol moieties may not become released from PEGs when administered in the body.
- these compounds have been used primarily for cosmetic applications, particularly for skin and hair care products, but still not for food additives.
- compositions for water-based food additives for reducing cholesterol absorption include an aqueous based micellar mix which is dried to provide a mixture of finely divided plant sterol and lecithin. Because the mixture is in micellar form, its use as food additives is believed to be significantly restricted.
- U.S. Patent No. 5,880,131 discloses a compound having taxols coupled to polyethylene glycols with a molecular weight ranging from 20,000 to 80,000 for the purpose of making water soluble taxol derivatives. While the resulting compound is soluble in water, it is not suitable for use as cholesterol-reducing food additives. Therefore, there are strong reasons for exploring and developing water-soluble sterol derivatives for wide and convenient use as cholesterol-reducing food additives and/or supplements.
- the present inventors have made an effort to solve the said problems, and prepared novel water-soluble sterol derivatives for inhibiting intestinal cholesterol absorption by reacting phytosterol with succinic anhydride or glutaric anhydride to obtain intermediate compounds, and coupling the intermediate compounds with hydrophilic polymer to prepare the water-soluble sterol derivatives, thereby phytosterol moieties can be released from the hydrophilic polymer in the intestine.
- a primary object of the present invention is, therefore, to provide water-soluble sterol derivatives for inhibiting intestinal cholesterol absorption.
- the other object of the invention is to provide a process for preparing the water-soluble sterol derivatives by reacting phytosterol with succinic anhydride or glutaric anhydride, and coupling with hydrophilic polymer.
- Figure 1 is a reaction scheme for the intermediate compound of the present invention.
- Figure 2 is 1 H-NMR spectrum of phytosterol derivative prepared by the present invention.
- the present invention provides water-soluble sterol derivatives for inhibiting intestinal cholesterol absorption.
- the sterol derivatives have phytosterols coupled to hydrophilic polymers by chemical bonds that can be hydrolyzed by enzymes in the intestine when the phytosterol derivatives are orally administered in animals.
- the chemical bonds between the phytosterols and the hydrophilic polymers are biodegradable in the intestine by enzymes present therein such that phytosterol moieties can be released from hydrophilic polymer moieties for inhibiting intestinal absorption of cholesterol.
- ester and/or amide bonds are preferably employed.
- phytosterol Various types and forms of phytosterol, including phytostanols, may be used for the phytosterol derivatives of the present invention. Accordingly, in describing the water-soluble sterol derivative of the invention, the term “phytosterols” is employed to mean all types, forms and/or mixtures of phytosterols and phytostanols such as stigmasterol, spinasterol, campesterol, sitosterol, sitostanol and campestanol; and, the term “hydrophilic polymers” is employed to mean water-soluble carriers that can bond with the intermediate compounds by chemical bonds capable of being hydrolyzed (i . e .
- hydrophilic polymers are provided for illustration purposes only and are not meant to limit the scope of the present invention. Accordingly, while any of the foregoing hydrophilic polymers can be used, PEGs having an average molecular weight ranging from 500 to 4,000, preferably from 1,000 to 3,000, and more preferably from 1,000 to 2,000 are suitable for use as hydrophilic polymers.
- the process for preparing the phytosterol derivatives of the present invention comprises the steps of: obtaining intermediate compounds by reacting phytosterols and succinic or glutaric anhydride in a non-polar solvent in the presence of a basic catalyst; and, coupling the intermediate compounds with hydrophilic polymers in a non- polar organic solvent in the presence of a basic catalyst and a coupling agent.
- the process for preparing the water-soluble phytosterol derivatives of the present invention is described in more detail by the following steps.
- Phytosterol and succinic or glutaric anhydride are dissolved in a non-polar solvent in a molar ratio of 1:1.0 to 1:1.5 and more preferably 1:1.3, a basic catalyst is subsequently added, and heated to a temperature preferably ranging from 40 to 150 ° C and more preferably to the boiling temperature of the non-polar organic solvent preferably for 2 to 20 hours and more preferably for 4 to 9 hours.
- non-polar organic solvent While toluene, methylene chloride, dichloroethane, tetrahydrofuran, benzene and diethylether are preferably employed as the non-polar organic solvent, other non-polar solvents may be used; and, 4-dimethylaminopyridine (DMAP) , pyridine and triethylamine may be used as the basic catalyst. After the starting materials disappear in TLC, the non-polar solvent is evaporated from the reaction mixture to give a solid residue.
- DMAP 4-dimethylaminopyridine
- the intermediate compounds (I) obtained in Step 1 and a hydrophilic polymer such as PEG, are dissolved in a non- polar organic solvent in the presence of basic catalyst in a molar ratio ranging from 1:1 to 2:1.
- a coupling agent are added, stirred at room temperature for about 5 to 15 hours, then filtered to remove byproduct.
- the non-polar organic solvent and basic catalyst used in Step I may be employed, and 1, 3-dicyclohexylcarbodiimide (DCC) , 1-3-diiso- propylcarbodiimide (DIPC) , 1-ethyl-3- ( 3 ' -dimethylamino- propyl) -carbodiimide, oxalyl chloride, carbonyl diimidazole, 2-chloropyridium, 2 , 2 ' -dipyridyl disulfide and 2-imidazoyl disulfide are preferably used as the coupling agent.
- DCC 3-dicyclohexylcarbodiimide
- DIPC 1-3-diiso- propylcarbodiimide
- 1-ethyl-3- ( 3 ' -dimethylamino- propyl) -carbodiimide 1-ethyl-3- ( 3 ' -dimethylamino- propyl) -car
- n is an integer ranging from 22 to 90; and, R is selected from the group consisting of -H,
- the cholesterol lowering effect of the phytosterol derivatives of the present invention was investigated by employing experimental animals.
- a study undertaken to investigate the solubility of the phytosterol derivatives also demonstrated that the phytosterol derivatives are soluble in water. Accordingly, the phytosterol derivatives of the present invention may be incorporated directly in water- based foodstuffs (e . g. , beverages) in any conventional manner .
- the intermediate compound were prepared in an analogous manner as in Example 1-1 except for using ⁇ - sitosterol and succinic anhydride in a molar ratio of
- the structure of the ⁇ -sitosterol derivatives was confirmed by X H-NMR in CDC1 3 , whose spectrum is disclosed in Figure 2.
- the X H-NMR spectrum confirmed that ⁇ - sitosterol was coupled to PEG by an ester bond.
- the degree of substitution (DS) of the ⁇ -sitosterol derivatives which is defined as the average molar number of sterol moieties per one molecule of phytosterol derivatives, was determined to be about 1.09, based on the X H-NMR spectrum and the following equation:
- n is the degree of polymerization of PEG; and, a, b and c are the integrations of the peaks assigned in Figure 2.
- the molecular weight of PEG does not have a significant effect on the degree of substitution of the phytosterol derivatives of the present invention.
- the solubility of the phytosterol derivatives of the present invention was measured by dissolving various samples in water and leaving to stand the mixture for 2 days at different temperatures, whose results are shown in Table 2 below.
- the phytosterol derivatives prepared with PEG having a molecular weight 1,000, 1,500, 2,000 and 4 , 000 are soluble in water. While the phytosterol derivatives of 4,000 PEG is more soluble in water than the phytosterol derivatives of 1,000, 1,500 and 2,000 PEG on the basis of weight concentration of phytosterol derivatives, the phytosterol derivatives of 1,000, 1,500 and 2,000 PEG are more soluble in water than the phytosterol derivatives of 4,000 PEG on the basis of sterol moiety.
- Example 3-3 :
- the solubility of Samples 4 of Table 3 above in water was measured under the temperatures indicated in Table 4 below.
- the solubility in water at 4°C was measured to be higher than 1.0 wt% based on the amount of sterol moieties (i . e . , higher than lOmg of sterol moieties per 1 ml of water) . It was also demonstrated that temperature does not have a significant effect on the solubility of the phytosterol derivatives .
- the amount of sterol moieties generally recommended for reducing serum cholesterol levels is about 2.7 grams per day (see : Weststrate et al . , Eur . J. Clin . Nutr . , 52:334-343, 1998; Johns et al . , Can . J. Physiol Pharmacol , 75:217-227 , 1997; Vanhanen et al . , Clin . Chim . Acta , 205:97-107, 1992; Gylling et al., J. Lip . Res .
- Phytosterol derivatives ( III ) were prepared by using monomethyl ether-PEG (MME-PEG) , one end of which is blocked by a methyl ether group: 5g of MME-PEG having a molecular weight of 2000, 0.68g of DCC and 0.07g of DMAP were dissolved in a small amount of methylene chloride at room temperature. 1.54g(1.2 times to the moles of MME-PEG) of the intermediate compound (I) obtained in Example 1-2 was pre-dissolved in methylene chloride and was then added in a dropwise at 30°C to the MME-PEG/DCC/DMAP mixture.
- MME-PEG monomethyl ether-PEG
- n is an integer ranging from 22 to 90.
- ⁇ -NMR spectrum of the phytosterol derivatives (III) demonstrated that all hydroxyl groups of MME-PEG were reacted with the intermediate compounds (I) and coupled with phytosterols.
- the degree of substitution of the phytosterol derivatives ( III ) is one, while the solubility was measured to be substantially identical to that of Sample 2, Table 4.
- each of the rats in Groups 3 and 4 was also administered with the amount of phytosterol derivatives equal to three and five, respectively, times the total amount of the administered cholesterol (s_e_e_: Table 5 below), while each of the rats in Groups 5 and 6 was administered with the amount of the phytosterol derivatives equivalent, in terms of sterol moiety, to three and five, respectively, times the total amount of the administered cholesterol (,se_e: Table 5) .
- the rats were not given any rations or water for the three hour period immediately following the cholesterol/ ⁇ -sitosterol/phytosterol derivative administration. Subsequently, the rats were given free access to rations and water until 9 AM the next morning.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU29466/00A AU2946600A (en) | 1999-03-04 | 2000-03-03 | Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990007121A KR100292672B1 (ko) | 1999-03-04 | 1999-03-04 | 콜레스테롤 저하효과를 갖는 수용성 피토스테롤 유도체의 제조방법 및 그로부터 제조되는 화합물 |
KR1999/0007121 | 1999-03-04 | ||
KR1019990007975A KR100292673B1 (ko) | 1999-03-10 | 1999-03-10 | 콜레스테롤 저하효과를 갖는 수용성 피토스테롤 유도체의 제조를 위한 중간체 화합물 |
KR1999/0007975 | 1999-03-10 | ||
US43284299A | 1999-11-01 | 1999-11-01 | |
US09/432,842 | 1999-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000052029A1 true WO2000052029A1 (fr) | 2000-09-08 |
Family
ID=27349916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2000/000170 WO2000052029A1 (fr) | 1999-03-04 | 2000-03-03 | Derive de sterol hydrosoluble inhibant l'absorption de cholesterol et procede d'elaboration |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2946600A (fr) |
WO (1) | WO2000052029A1 (fr) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020081834A (ko) * | 2001-04-20 | 2002-10-30 | 주식회사 유엘바이오텍 | 식물성 스테롤의 유도체를 이용한 혈중 콜레스테롤저하제의 제조방법 및 이에 의해 제조된 혈중 콜레스테롤저하제 |
US6677327B1 (en) | 1999-11-24 | 2004-01-13 | Archer-Daniels-Midland Company | Phytosterol and phytostanol compositions |
EP1382662A1 (fr) * | 2001-04-27 | 2004-01-21 | Ajinomoto Co., Inc. | Compositions de sterols, compositions de matieres grasses et aliments contenant lesdites compositions de sterols |
KR100440613B1 (ko) * | 2001-04-20 | 2004-08-16 | 주식회사 유엘바이오텍 | 식물성스테롤과 생 플라보노이드의 결합체를 이용한 혈중콜레스테롤 저하제의 제조방법과 이에 의해 제조한 혈중콜레스테롤 저하제 |
WO2004083229A1 (fr) * | 2003-03-19 | 2004-09-30 | Cognis Ip Management Gmbh | Sterol-esters ou stanol-esters d'acides ethercarboxyliques |
US7306819B2 (en) | 2002-06-12 | 2007-12-11 | The Coca-Cola Company | Beverages containing plant sterols |
US7335389B2 (en) | 2002-06-12 | 2008-02-26 | The Coca-Cola Company | Beverages containing plant sterols |
WO2008032980A1 (fr) * | 2006-09-12 | 2008-03-20 | Cns Pharm Korea Co., Ltd. | Nouveau dérivé de stigmastérol ou sel pharmaceutiquement acceptable correspondant, procédé de production, et composition contenant ce produit pour lutter contre l'obésité ou prévenir et traiter l'hyperlipidémie |
US7368138B2 (en) | 2002-03-21 | 2008-05-06 | Archer-Daniels-Midland Company | Extraction of phytosterols from corn fiber using green solvents |
US7811781B2 (en) | 2005-07-06 | 2010-10-12 | Btg International Limited | Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis |
US7906493B2 (en) | 2003-12-22 | 2011-03-15 | Btg International Limited | Core 2 GlcNAc-T inhibitors |
US7998943B2 (en) | 2005-07-06 | 2011-08-16 | Btg International Limited | Core 2 GlcNAc-T inhibitors III |
EP1985308A3 (fr) * | 1999-04-02 | 2011-11-16 | National Research Council of Canada | Composition soluble dans l'eau de bioactifs lipophiles |
US8197794B2 (en) | 2003-12-22 | 2012-06-12 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
JP2013522298A (ja) * | 2010-03-12 | 2013-06-13 | ケーアイピー バイオテック リミテッド ライアビリティ カンパニー | コレステロールを低減するための水溶性フィトステロール誘導体およびその調製法 |
US8609633B2 (en) | 2005-07-06 | 2013-12-17 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
EP2755660A4 (fr) * | 2011-09-16 | 2015-03-18 | Davidson Lopez Llc | Stéroïdes végétaux et leurs utilisations |
TWI741660B (zh) | 2020-06-29 | 2021-10-01 | 萬能學校財團法人萬能科技大學 | 谷甾醇型界面活性劑之製備及其應用 |
EP3852765A4 (fr) * | 2018-09-19 | 2022-06-22 | ModernaTX, Inc. | Purification de stérol |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB938937A (en) * | 1959-10-09 | 1963-10-09 | Eastman Kodak Co | Water-soluble vegetable oil sterol derivatives |
US4183847A (en) * | 1976-08-23 | 1980-01-15 | Deshmukh Arvind D | Enzymatically hydrolyzable, serum-soluble cholesterol compounds and method for their preparation |
JPH10330422A (ja) * | 1997-05-29 | 1998-12-15 | Res Dev Corp Of Japan | 胆汁酸吸着性樹脂 |
WO1999015546A1 (fr) * | 1997-09-09 | 1999-04-01 | Raisio Benecol Ltd. | Utilisation d'acides d'esters organiques dans les graisses alimentaires |
-
2000
- 2000-03-03 WO PCT/KR2000/000170 patent/WO2000052029A1/fr active Application Filing
- 2000-03-03 AU AU29466/00A patent/AU2946600A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB938937A (en) * | 1959-10-09 | 1963-10-09 | Eastman Kodak Co | Water-soluble vegetable oil sterol derivatives |
US4183847A (en) * | 1976-08-23 | 1980-01-15 | Deshmukh Arvind D | Enzymatically hydrolyzable, serum-soluble cholesterol compounds and method for their preparation |
JPH10330422A (ja) * | 1997-05-29 | 1998-12-15 | Res Dev Corp Of Japan | 胆汁酸吸着性樹脂 |
WO1999015546A1 (fr) * | 1997-09-09 | 1999-04-01 | Raisio Benecol Ltd. | Utilisation d'acides d'esters organiques dans les graisses alimentaires |
Non-Patent Citations (3)
Title |
---|
J. MED. CHEM., vol. 27, no. 10, 1984, pages 1306 - 1312 * |
LIPIDS, vol. 26, no. 3, 1991, pages 209 - 212 * |
OBSHCH. KHIM., vol. 47, no. 6, 1997, pages 1429 - 1430 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1985308A3 (fr) * | 1999-04-02 | 2011-11-16 | National Research Council of Canada | Composition soluble dans l'eau de bioactifs lipophiles |
US6677327B1 (en) | 1999-11-24 | 2004-01-13 | Archer-Daniels-Midland Company | Phytosterol and phytostanol compositions |
KR100440613B1 (ko) * | 2001-04-20 | 2004-08-16 | 주식회사 유엘바이오텍 | 식물성스테롤과 생 플라보노이드의 결합체를 이용한 혈중콜레스테롤 저하제의 제조방법과 이에 의해 제조한 혈중콜레스테롤 저하제 |
KR20020081834A (ko) * | 2001-04-20 | 2002-10-30 | 주식회사 유엘바이오텍 | 식물성 스테롤의 유도체를 이용한 혈중 콜레스테롤저하제의 제조방법 및 이에 의해 제조된 혈중 콜레스테롤저하제 |
EP1382662A4 (fr) * | 2001-04-27 | 2009-12-23 | Ajinomoto Kk | Compositions de sterols, compositions de matieres grasses et aliments contenant lesdites compositions de sterols |
EP1382662A1 (fr) * | 2001-04-27 | 2004-01-21 | Ajinomoto Co., Inc. | Compositions de sterols, compositions de matieres grasses et aliments contenant lesdites compositions de sterols |
US8114447B2 (en) | 2002-03-21 | 2012-02-14 | Archer Daniels Midland Company | Extraction of phytosterols from corn fiber using green solvents |
US7368138B2 (en) | 2002-03-21 | 2008-05-06 | Archer-Daniels-Midland Company | Extraction of phytosterols from corn fiber using green solvents |
US7306819B2 (en) | 2002-06-12 | 2007-12-11 | The Coca-Cola Company | Beverages containing plant sterols |
US7335389B2 (en) | 2002-06-12 | 2008-02-26 | The Coca-Cola Company | Beverages containing plant sterols |
WO2004083229A1 (fr) * | 2003-03-19 | 2004-09-30 | Cognis Ip Management Gmbh | Sterol-esters ou stanol-esters d'acides ethercarboxyliques |
US8197794B2 (en) | 2003-12-22 | 2012-06-12 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
US7906493B2 (en) | 2003-12-22 | 2011-03-15 | Btg International Limited | Core 2 GlcNAc-T inhibitors |
US7811781B2 (en) | 2005-07-06 | 2010-10-12 | Btg International Limited | Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis |
US7998943B2 (en) | 2005-07-06 | 2011-08-16 | Btg International Limited | Core 2 GlcNAc-T inhibitors III |
US8609633B2 (en) | 2005-07-06 | 2013-12-17 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
WO2008032980A1 (fr) * | 2006-09-12 | 2008-03-20 | Cns Pharm Korea Co., Ltd. | Nouveau dérivé de stigmastérol ou sel pharmaceutiquement acceptable correspondant, procédé de production, et composition contenant ce produit pour lutter contre l'obésité ou prévenir et traiter l'hyperlipidémie |
KR100886466B1 (ko) * | 2006-09-12 | 2009-03-04 | (주)한국씨엔에스팜 | 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물 |
JP2013522298A (ja) * | 2010-03-12 | 2013-06-13 | ケーアイピー バイオテック リミテッド ライアビリティ カンパニー | コレステロールを低減するための水溶性フィトステロール誘導体およびその調製法 |
EP2755660A4 (fr) * | 2011-09-16 | 2015-03-18 | Davidson Lopez Llc | Stéroïdes végétaux et leurs utilisations |
US10086082B2 (en) | 2011-09-16 | 2018-10-02 | Davidson Lopez Llc | Plant steroids and uses thereof |
EP3852765A4 (fr) * | 2018-09-19 | 2022-06-22 | ModernaTX, Inc. | Purification de stérol |
TWI741660B (zh) | 2020-06-29 | 2021-10-01 | 萬能學校財團法人萬能科技大學 | 谷甾醇型界面活性劑之製備及其應用 |
Also Published As
Publication number | Publication date |
---|---|
AU2946600A (en) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000052029A1 (fr) | Derive de sterol hydrosoluble inhibant l'absorption de cholesterol et procede d'elaboration | |
US3004043A (en) | Water-soluble vegetable oil sterol derivatives | |
HU228301B1 (en) | Stanol composition and the use thereof | |
HU216636B (hu) | Eljárás epesavszármazékok előállítására | |
CZ289515B6 (cs) | Tetrazolové deriváty ľlučových kyselin a léčivo tyto deriváty obsahující | |
FR2476093A1 (fr) | Nouveaux composes 3-hydroxy ou 3-acyloxy 1,3,5(10)-estratriene-17b-oxycarbonylmethyle et leur application en therapeutique | |
US7645749B2 (en) | Sterol/stanol nitroderivatives and use thereof | |
US5270335A (en) | Method of inhibiting metabolism of cholesterol | |
WO1999039715A1 (fr) | Phytosterols facilement absorbables permettant de traiter l'hypercholesterolemie | |
JPS6075495A (ja) | 胆汁酸誘導体、それらの製造法及びそれらを含む薬学的組成物 | |
JP2010511393A (ja) | オリーブオイルの生産から得られる植物水をベースとした新規な粉末 | |
WO2000061694A1 (fr) | Procede de fabrication d'ester de phytosterol ou du phytostanol liposoluble d'un acide gras insature | |
CN107973835B (zh) | 天然混合植物甾醇儿茶素、制备方法及应用 | |
Han et al. | Synthesis and anti-hyperlipidemic activity of a novel starch piperinic ester | |
WO2013113294A1 (fr) | Dérivé de stérol, son procédé de préparation et son utilisation | |
KR100292672B1 (ko) | 콜레스테롤 저하효과를 갖는 수용성 피토스테롤 유도체의 제조방법 및 그로부터 제조되는 화합물 | |
KR100292673B1 (ko) | 콜레스테롤 저하효과를 갖는 수용성 피토스테롤 유도체의 제조를 위한 중간체 화합물 | |
Jung et al. | Prednisolone 21‐sulfate sodium: a colon‐specific pro‐drug of prednisolone | |
KR100436920B1 (ko) | 인삼으로부터 추출한 신규한 폴리아세틸렌계 화합물, 그의추출방법 및 이를 함유하는 비만치료제 | |
US20040034079A1 (en) | Imidazole alkaloids from lepidium meyenii and methods of usage | |
JP7120561B2 (ja) | 糖及び/又は脂質の代謝改善剤 | |
WO2010114320A2 (fr) | Dérivés de stérol hydrosolubles pour abaisser les taux de cholestérol et procédé pour produire ceux-ci | |
JP2004508282A (ja) | 新規なトララクトン及びその誘導体、並びに血中脂質低下及び体重減少のためのその使用 | |
WO2010126276A2 (fr) | Dérivés de stérol hydrosolubles pour abaisser le niveau de cholestérol et procédé de préparation correspondant | |
KR100697183B1 (ko) | 신규한 스테릴 에스테르 화합물 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |